Karuna Therapeutics Stock Shares Owned By Insiders
Karuna Therapeutics fundamentals help investors to digest information that contributes to Karuna Therapeutics' financial success or failures. It also enables traders to predict the movement of Karuna Stock. The fundamental analysis module provides a way to measure Karuna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Karuna Therapeutics stock.
Karuna |
Karuna Therapeutics Company Shares Owned By Insiders Analysis
Karuna Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Karuna Therapeutics Shares Owned By Insiders | 4.98 % |
Most of Karuna Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Karuna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 4.98% of Karuna Therapeutics are shares owned by insiders. This is 67.19% lower than that of the Biotechnology sector and 64.88% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 50.64% higher than that of the company.
Karuna Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karuna Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Karuna Therapeutics could also be used in its relative valuation, which is a method of valuing Karuna Therapeutics by comparing valuation metrics of similar companies.Karuna Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Karuna Fundamentals
| Return On Equity | -0.36 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (755.64) % | |||
| Current Valuation | 11.35 B | |||
| Shares Outstanding | 38.2 M | |||
| Shares Owned By Insiders | 4.98 % | |||
| Shares Owned By Institutions | 86.32 % | |||
| Number Of Shares Shorted | 1.97 M | |||
| Price To Earning | (19.88) X | |||
| Price To Book | 10.05 X | |||
| Price To Sales | 19,265 X | |||
| Revenue | 654 K | |||
| Gross Profit | 10.64 M | |||
| EBITDA | (493.08 M) | |||
| Net Income | (433.68 M) | |||
| Cash And Equivalents | 407.41 M | |||
| Cash Per Share | 13.60 X | |||
| Total Debt | 16.69 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 17.77 X | |||
| Book Value Per Share | 32.94 X | |||
| Cash Flow From Operations | (385.82 M) | |||
| Short Ratio | 3.60 X | |||
| Earnings Per Share | (11.74) X | |||
| Price To Earnings To Growth | 1.46 X | |||
| Target Price | 324.17 | |||
| Number Of Employees | 339 | |||
| Beta | 1.15 | |||
| Market Capitalization | 12.6 B | |||
| Total Asset | 1.34 B | |||
| Retained Earnings | (997.89 M) | |||
| Working Capital | 1.25 B | |||
| Current Asset | 6.24 M | |||
| Current Liabilities | 8.73 M | |||
| Net Asset | 1.34 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Karuna Stock
If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |